We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
Cap. Flow
-$236M
Cap. Flow %
-5.9%
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$81.8M
2
UNH icon
UnitedHealth
UNH
+$51.6M
3
ROIV icon
Roivant Sciences
ROIV
+$30.1M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.2M
5
JBIO
Jade Biosciences
JBIO
+$18.1M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$97.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$76.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$56.9M
4
SWTX
SpringWorks Therapeutics
SWTX
+$41.9M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Miscellaneous 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSPR icon
76
InspireMD
NSPR
$39.8M
$4.84M 0.12%
2,133,405
– –
AVTX icon
77
Avalo Therapeutics
AVTX
$1.05B
$4.83M 0.12%
967,000
– –
IMA
78
ImageneBio Inc
IMA
$60.6M
$4.74M 0.12%
294,947
– –
RPTX
79
DELISTED
Repare Therapeutics
RPTX
$4.62M 0.12%
3,322,488
– –
CGON icon
80
CALL
CG Oncology
CGON
$6.59B
$3.9M 0.1%
+150,000
New +$3.61M
IMTX icon
81
Immatics
IMTX
$1.44B
$3.87M 0.1%
719,901
-2,367,561
-77% -$11.7M
BIOA
82
BioAge Labs
BIOA
$443M
$3.81M 0.1%
921,959
– –
QTTB icon
83
Q32 Bio
QTTB
$447M
$3.36M 0.08%
2,252,987
– –
ENGN icon
84
enGene Therapeutics
ENGN
$122M
$2.47M 0.06%
677,977
-213,639
-24% -$802K
PASG icon
85
Passage Bio
PASG
$14.5M
$2.42M 0.06%
302,765
-48,966
-14% -$358K
AMLX icon
86
Amylyx Pharmaceuticals
AMLX
$3.87B
$2.01M 0.05%
313,200
-34,800
-10% -$169K
MURA
87
DELISTED
Mural Oncology
MURA
$1.45M 0.04%
+588,800
New +$1.39M
INSM icon
88
Insmed
INSM
$25.9B
$1.35M 0.03%
13,459
-15,200
-53% -$1.16M
KRYS icon
89
Krystal Biotech
KRYS
$10.4B
$1.26M 0.03%
9,200
-14,300
-61% -$2.1M
TSBX
90
DELISTED
Turnstone Biologics
TSBX
$1.11M 0.03%
3,099,265
– –
CMMB
91
Chemomab Therapeutics
CMMB
$19.9M
$1.09M 0.03%
235,248
-200,070
-46% -$990K
TRAW icon
92
Traws Pharma
TRAW
$9.07M
$896K 0.02%
605,531
– –
KZR
93
DELISTED
Kezar Life Sciences
KZR
$883K 0.02%
192,700
– –
APLS
94
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$866K 0.02%
+50,000
New +$926K
ANRO icon
95
Alto Neuroscience
ANRO
$1.38B
$550K 0.01%
250,000
– –
DHAI
96
DELISTED
DIH Holdings US
DHAI
$469K 0.01%
76,600
– –
LYEL icon
97
Lyell Immunopharma
LYEL
$356M
$457K 0.01%
+51,727
New +$471K
KRRO icon
98
Korro Bio
KRRO
$190M
$405K 0.01%
32,400
– –
XERS icon
99
Xeris Biopharma Holdings
XERS
$1.55B
$376K 0.01%
80,420
– –
INMB icon
100
PUT
INmune Bio
INMB
$64.7M
$116K ﹤0.01%
+50,000
New +$367K
2 3
4
5 6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2025 Portfolio in Review

As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.

  • OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
  • OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
  • OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
  • OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
  • OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
  • OrbiMed opened 18 new positions and closed 26 in Q2 2025.
  • OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.